Back

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

Lovly, C. M.; Boyd, K. L.; Gonzalez-Ericsson, P. I.; Lowe, C. L.; Brown, H. M.; Hoffman, R. D.; Sterling, B. C.; Kapp, M. E.; Johnson, D. B.; Kopparapu, P. R.; Iams, W. T.; Warren, M. A.; Noto, M. J.; Rini, B. I.; Jagasia, M.; Das, S. R.; Balko, J. M.

2020-05-01 oncology
10.1101/2020.04.29.20085738 medRxiv
Show abstract

Immune checkpoint inhibitors (ICIs) are used for the treatment of numerous cancers, but risks associated with ICI-therapy during the COVID-19 pandemic are poorly understood. We report a case of acute lung injury in a lung cancer patient initially treated for ICI-pneumonitis and later found to have concurrent SARS-CoV-2 infection. Post-mortem analyses revealed diffuse alveolar damage in both the acute and organizing phases, with a predominantly CD68+ inflammatory infiltrate. Serum was positive for anti-SARS-CoV-2 IgG, suggesting that viral infection predated administration of ICI-therapy and may have contributed to a more fulminant clinical presentation. These data suggest the need for routine SARS-CoV-2 testing in cancer patients, where clinical and radiographic evaluations may be non-specific.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.